| [1] |
谢幸， 苟文丽. 妇产科学. 8版[M]. 北京： 人民卫生出版社， 2013: 64-71.
|
| [2] |
Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia[J]. J Leukoc Biol, 2013, 94(2): 247-257.
|
| [3] |
Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, et al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia[J]. J Reprod Immunol, 2012, 93(2): 75-81.
|
| [4] |
Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor[J]. Immunity, 1995, 3(6): 811-821.
|
| [5] |
Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling[J]. Cytokine, 2013, 64(2): 477-485.
|
| [6] |
Cornelius DC, Hogg JP, Scott J, et al. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy[J]. Hypertension, 2013, 62(6): 1068-1073.
|
| [7] |
Cornelius DC, Lamarca B. TH17- and IL-17- mediated autoantibodies and placental oxidative stress play a role in the pathophysiology of pre-eclampsia[J]. Minerva Ginecol, 2014, 66(3): 243-249.
|
| [8] |
Saifi B, Rezaee SA, Tajik N, et al. Th17 cells and related cytokines in unexplained recurrent spontaneous miscarriage at the implantation window[J]. Reprod Biomed Online, 2014, 29(4): 481-489.
|
| [9] |
汪勤， 赵春辉， 夏良萍， 等. 重度子痫前期患者外周血Th17和Treg细胞及相关细胞因子的表达及意义[J]. 检验医学与临床， 2015, 12(20): 3040-3043.
|
| [10] |
Toldi G, Rigó J Jr, Stenczer B, et al. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia[J]. Am J Reprod Immunol, 2011, 66(3): 223-229.
|
| [11] |
Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin[J]. Proc Natl Acad Sci USA, 1997, 94(22): 12041-12046.
|
| [12] |
Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569.
|
| [13] |
Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J]. Eur J Immunol, 2007, 37(11): 3021-3029.
|
| [14] |
Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance[J]. Front Immunol, 2013, 4: 315.
|
| [15] |
Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012, 13(3): 290-299.
|
| [16] |
Aparicio-Siegmund S, Moll JM, Lokau J, et al. Recombinant p35 from bacteria can form interleukin (IL-)12, but not IL-35[J]. PLoS One, 2014, 9(9): e107990.
|
| [17] |
Jin E, Wang C, Hu Q, et al. The regular distribution and expression pattern of immunosuppressive cytokine IL-35 in mouse uterus during early pregnancy[J]. Rom J Morphol Embryol, 2014, 55(4): 1353-1361.
|
| [18] |
Yue CY, Zhang B, Ying CM. Elevated serum level of IL-35 associated with the maintenance of maternal-fetal immune tolerance in normal pregnancy[J]. PLoS One, 2015, 10(6): e0128219.
|
| [19] |
潘秀和， 彭笑， 高巧艳， 等. IL-35在感染、炎症与自身免疫性疾病中的作用[J]. 中华微生物学和免疫学杂志， 2015, 35(3): 237-240.
|
| [20] |
Cao W, Wang X, Chen T, et al. The Expression of Notch/Notch ligand, IL-35, IL-17, and Th17/Treg in preeclampsia[J]. Dis Markers, 2015, 2015: 316182.
|
| [21] |
闫永嘉， 何向辉. IL-35结构功能及其调控Treg细胞免疫抑制功能的研究进展[J]. 天津医药， 2014, 42(12): 1243-1245.
|
| [22] |
Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4＋effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol, 2005, 6(11): 1123-1132.
|
| [23] |
Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol, 2005, 6(11): 1133-1141.
|
| [24] |
Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol, 1995, 155(3): 1151-1164.
|
| [25] |
Schumacher A, Wafula PO, Teles A, et al. Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells[J]. PLoS One, 2012, 7(8): e42301.
|
| [26] |
魏志霞， 杨海澜， 韩方. Foxp3和RORγt基因在子痫前期患者外周血单个核细胞中的表达[J]. 中华妇产科杂志， 2013, 48(3): 204-206.
|
| [27] |
Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties[J]. Annu Rev Immunol, 1989, 7: 145-173.
|
| [28] |
Vargas-Rojas MI, Solleiro-Villavicencio H, Soto-Vega E. Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia[J]. J Matern Fetal Neonatal Med, 2016, 29(10): 1642-1645.
|
| [29] |
Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity[J]. Cytokine, 2015, 72(2): 146-153.
|
| [30] |
尹雪， 任秀敏， 刘春苗， 等. 变应性鼻炎患者IL-35对于Treg/Th17细胞平衡的调控作用[J]. 临床耳鼻喉头颈外科杂志， 2016, 30(3): 213-216.
|
| [31] |
Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus[J]. Clin Immunol, 2014, 154(1): 1-12.
|
| [32] |
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase Ⅱ dose-ranging study[J]. Br J Dermatol, 2013, 168 (2): 412-421.
|
| [33] |
Li HC, Zhang YX, Liu Y, et al. Effect of IL-17 monoclonal antibody secukinumab combined with IL-35 blockade of Notch signaling pathway on the invasive capability of hepatoma cells[J]. Genet Mol Res, 2016, 15(2): 238-242.
|
| [34] |
Long J, Zhang X, Wen M, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells[J]. Biochem Biophys Res Commun, 2013, 430(1): 364-369.
|
| [35] |
Nakano S, Morimoto S, Suzuki S, et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis[J]. Rheumatology (Oxford), 2015, 54 (8): 1498-1506.
|